Imaging of treatment response during systemic therapy for hepatocellular carcinoma

William R. Masch, Rony Kampalath, Neehar Parikh, Kimberly A. Shampain, Anum Aslam, Victoria Chernyak

Research output: Contribution to journalReview articlepeer-review

Abstract

Systemic therapy for the treatment of hepatocellular carcinoma (HCC) has rapidly evolved over the last 4 years; eight new drug regimens have gained Food and Drug Administration approval for treatment of advanced HCC since 2017. As several lines of therapy are now available for the treatment of HCC, accurate CT and MRI treatment response assessment is important for informing optimal management of affected patients. This article will review the systemic therapies currently approved for the treatment of HCC, focusing on items most pertinent to radiologists. Treatment response assessment of patients with HCC undergoing systemic therapy differs from treatment response assessment of patients receiving locoregional therapies, and principle differences will be highlighted. Finally, this review will provide a framework for the interpretation of CT and MRI examinations of patients with HCC being treated with systemic therapy and will explore the relevant scientific data currently available.

Original languageEnglish (US)
Pages (from-to)3625-3633
Number of pages9
JournalAbdominal Radiology
Volume46
Issue number8
DOIs
StatePublished - Aug 2021

Keywords

  • CT
  • Hepatocellular carcinoma
  • MRI
  • Systemic therapy
  • Treatment Response Assessment

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Fingerprint

Dive into the research topics of 'Imaging of treatment response during systemic therapy for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this